Parkinson's disease is characterized by the progressive degeneration of nigrostriatal dopaminergic neurons in the ventral midbrain. Although the basic underlying mechanisms of this debilitating movement disorder remain unknown, considerable efforts have centered on developing effective strategies for halting the neurodegenerative process and restoring normal function. One promising approach involves the use of neurotrophic factors, proteins that promote the survival and proper functioning of select populations of neurons. Preliminary findings from our laboratory show that receptor mRNA and protein for a relatively novel group of trophic factors called neuregulins are synthesized within the dopaminergic nigrostriatal system in rodents and primates. We find that supranigral administration of neuregulin induces increased dopamine overflow in the striatum, indicating functional effects upon the dopaminergic nigrostriatal system. Our recent data also indicate that neuregulin treatment protects dopaminergic cells against neurotoxin-induced degeneration in vivo, and against both oxidative and metabolic insults in vitro. In the proposed research, we will expand upon these findings to test the overall the hypothesis that neuregulins are neuroprotective and/ or neurorestorative for midbrain dopaminergic neurons upon selective neurotoxic damage.
Specific Aim #1 will determine the extent to which neuregulin receptors are expressed by dopaminergic cells in the ventral mesencephalon of normal and neurotoxin-lesioned rat and monkey using single- and double-labeling in situ hybridization and immunocytochemical techniques.
Specific Aim #2 will use a well-characterized rat model of Parkinson's disease coupled with specific neuregulin treatment regims to test if infusion of neuregulins (I) protects dopaminergic neurons from subsequent neurotoxic damage or (ii) promotes functional recovery of the injured nigrostriatal system after neurotoxic damage. Morphological, behavioral and neurochemical approaches will be used to analyze the extent of protection and/or functional restoration afforded by neuregulin treatment.
Specific aim #3 will (I) determine if neuregulin receptor expression is spatially or temporally deficient in the rat and monkey nigrostriatal system in aged animals, and (ii) using intracerebral microdialysis, evaluate the responsiveness of the dopaminergic nigrostriatal system to neuregulin administration in young, middle age and old rats.
Specific aim #4 will assess the potential mechanisms by which neuregulin protects dopaminergic cells from insults relevent to Parkinson's disease. Overall, these studies will assess the therapeutic value of neuregulin trophic factors for the treatment of Parkinson's disease and other neurodegenerative disorders of the nigrostriatal system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
7R01NS039128-04
Application #
6639597
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Murphy, Diane
Project Start
2000-04-10
Project End
2006-03-31
Budget Start
2003-04-01
Budget End
2006-03-31
Support Year
4
Fiscal Year
2003
Total Cost
$268,625
Indirect Cost
Name
University of Cincinnati
Department
Neurology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Hemmerle, Ann M; Dickerson, Jonathan W; Herring, Nicole R et al. (2012) (±)3,4-methylenedioxymethamphetamine (""ecstasy"") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain. J Comp Neurol 520:2459-74
Braun, A A; Herring, N R; Schaefer, T L et al. (2011) Neurotoxic (+)-methamphetamine treatment in rats increases brain-derived neurotrophic factor and tropomyosin receptor kinase B expression in multiple brain regions. Neuroscience 184:164-71
Dickerson, J W; Hemmerle, A M; Numan, S et al. (2009) Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats. Neuroscience 163:482-9
Cass, Wayne A; Peters, Laura E; Harned, Michael E et al. (2006) Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 1074:272-81
Herman, James P; Seroogy, Kim (2006) Hypothalamic-pituitary-adrenal axis, glucocorticoids, and neurologic disease. Neurol Clin 24:461-81, vi
Numan, Suzanne; Gall, Christine M; Seroogy, Kim B (2005) Developmental expression of neurotrophins and their receptors in postnatal rat ventral midbrain. J Mol Neurosci 27:245-60
Zhang, Lixin; Fletcher-Turner, Anita; Marchionni, Mark A et al. (2004) Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J Neurochem 91:1358-68
Yurek, David M; Zhang, Lixin; Fletcher-Turner, Anita et al. (2004) Supranigral injection of neuregulin1-beta induces striatal dopamine overflow. Brain Res 1028:116-9
Dimayuga, Filomena O; Ding, Qunxing; Keller, Jeffrey N et al. (2003) The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol 136:67-74
Lee, Jaewon; Seroogy, Kim B; Mattson, Mark P (2002) Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 80:539-47

Showing the most recent 10 out of 11 publications